Levent TÜTÜNCÜ, Yusuf TUNCA, Serkan BODUR, İlhami GÜL, Özgür DÜNDAR

The Status of Telomerase Enzyme Activity in Benign and Malignant Gynaecologic Pathologies

Background: Telomeres are essential for the function and stability of eukaryotic chromosomes. Telomerase consists of three subunits: human telomerase reverse transcriptase (hTERT), human telomerase RNA (hTR), and telomerase protein 1 (TP1). The hTERT subunit determines the activity of telomerase as an enzyme and is detected in most human tumors and regenerative cells. Telomerase activity is a useful cancer-cell detecting marker in some types of cancers.Aims: The aim of this study was to assess of telomerase hTERT mRNA in gynaecological tumors for diagnosis of malignancy.Study Design: Cross-sectional study.Methods: A total of 55 gynaecologic tumor samples (35 ovarian, 13 endometrial, 6 cervical and 1 placental site trophoblastic tumor tissue) were obtained at the time of surgery. Quantification of hTERT mRNA was performed in a real-time reverse transcriptase polymerase chain reaction (RT-PCR) using the LightCycler TeloTAGGG hTERT Quantification Kit.Results: It was histopathologically detected that 18 of the tissue samples were malignant and 37 of the samples were benign. 16 of the malignant tissue samples (88.9%) and 3 (8.1%) (endometrial tissue in proliferative phase, mucinous cyst adenoma and endometriosis) of the benign tissue samples were found to be hTERT positive. With the presence of these data, sensitivity and specificity of hTERT for the diagnosis of malignancy were calculated to be 88.9% and 91.9%, respectively.Conclusion: It was suggested that the measurement of telomerase activity in gynaecologic tumors, except for endometrial tissue in the reproductive phase, is a valuable method for pathological investigation.

PDF

___

1. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996;274:92-7. [CrossRef]
2. Blackburn EH. Switching and signaling at the telomere. Cell 2001;106:661-73. [CrossRef]
3. Goldstein S. Replicative Senescence: The Human Fibroblast Comes of Age. Science 1990;249:1129-33. [CrossRef]
4. Shay JW, Zou Y, Hiyama E, Wrigw E. Telomerase and Cancer. Hum Mol Genet 2001;10:677-85. [CrossRef]
5. Shay JW, Bacchetti S. A survey of Telomerase Activity in Human Cancer. Eur J Cancer 1997;33:787-91. [CrossRef]
6. Miura N, Kanamori Y, Takahashi M, Sato R, Tsukamoto T, Takahashi S, et al. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. 2007;17:541-8.
7. Carroll KA, Ly H. Functional characterization of mutations in the promoter proximal region of the telomerase hTERC gene identi- fied in patients with hematological disorders. Int J Clin Exp Med 2011;4:187-92.
8. Adler S, Rashid G, Klein A. Indole-3-carbinol inhibits telomerase activity and gene expression in prostate cancer cell lines. Anticancer Res 2011;31:3733-7.
9. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15:50-65. [CrossRef]
10. Jarboe EA, Liaw KL, Thompson LC, Heinz DE, Baker PL, McGregor JA, et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene 2002;21:664- 73. [CrossRef]
11. Mutirangura A, Sriuranpong V, Termrunggraunglert W, Tresukosol D, Lertsaguansinchai P, Voravud N, et al. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. Br J Cancer 1998;78:933-9. [CrossRef]
12. Nagai N, Oshita T, Murakami J, Ohama K. Semiquantitative analysis of telomerase activity in cervical cancer and precancerous lesions. Oncol Rep 1999;6:325-8.
13. Wisman GBA, Hollema H, de Jong S, ter Schegget J, Tjong-AHung SP, Ruiters MHJ, et al. Telomerase activity as biomarker for (pre)-neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smears. J Clin Oncol 1998;16:2238-45.
14. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, et al. Quantitative Analysis of Telomerase hTERT mRNA and TelomeraseActivity in Endometrioid Adenocarcinoma and in Normal Endometrium. Gynecologic Oncology 2002;84:120-5. [CrossRef]
15. Shroyer KR, Stephens JK, Silverberg SG, Markham N, Shroyer AL, Wilson ML, Enomoto T. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma. Int J Gynecol Pathol 1997;16:225-32. [CrossRef]
16. Williams CD, Boggess JF, Lamarque LR, Meyer WR, Murray MJ, Fritz MA, Lessey BA. A Prospective, Randomized Study of Endometrial Telomerase During the Menstrual Cycle. The J Clin Endocrinol Metab 2001;86:3912-7. [CrossRef]
17. Brustmann H. Immunohistochemical Detection of Human Telomerase Reverse Transcriptase (hTERT), Topoisomerase II ? Expression, and Apoptosis in Endometrial Adenocarcinoma and Atypical Hyperplasia. Int J Gynecol Pathol. 2005;24:184-92. [CrossRef]
18. Saygan-Karamursel B, Dikmen G, Dogan P, Aksu T, Guven S, Ayhan A. Quantitative telomerase activity in malignant, benign and normal gynecological tissues. Eur J Gynaecol Oncol 2005;26:83-6.
19. Datar RH, Naritoku WY, Li P, Tsao-Wei D, Groshen S, Taylor CR, et al. Analysis of telomerase activity in ovarian cystadenomas, lowmalignant-potential tumors, and invasive carcinomas. Gynecol Oncol 1999;74:338-45. [CrossRef]
20. Baykal A, Thompson JA, Xu XC, Hahn WC, Deavers MT, Malpica A, et al. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 2004;11:297-302.
21. Oishi T, Kigawa J, Minagava Y, Shimada M, Takahashi M, Terakawa N. Alteration of Telomerase Activity associated with development and extention of epitelyal ovaryan cancer. Obstet Gynecol, 91(4): 568-71, 1998. http://dx.doi.org/10.1016/S0029- 7844(98)00044-1. [CrossRef]
22. Wan M, Li W, Duggan B, Felix JC, Zhao Y, Dubeau L. Telomerase Activity in Benign and Malignant Epithelial Ovarian Tumors. J Natl Cancer Inst, 89: 437-41, 1997. http://dx.doi.org/10.1093/ jnci/89.6.437 PMid:9091645. [CrossRef]
23. Tseng CJ, Jain S, Hou H, Liu W, Pao C, Lin C, et al. Applications of the Telomerase Assay in Peritoneal Washing Fluids. Gynecol Oncol 2001;81:420-3. [CrossRef]
24. Duggan B, Wan M, Martin SE, Yu M, Kanel G, Muderspach LI. Sensitive detection of ovarian carcinoma cells by measurement of telomerase activity in ascites or pelvic-peritoneal washings. Proc Am Assoc Cancer Res 1997;38:106.
25. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 2002;123:217-26. [CrossRef]
26. Zafrakas M, Tarlatzis BC, Streichert T, Pournaropoulos F, Wölfle U, Smeets SJ, et al. Genome-wide microarray gene expression, array-CGH analysis, and telomerase activity in advanced ovarian endometriosis: a high degree of differentiation rather than malignant potential. Int J Mol Med 2008;21:335-44.
27. Hapangama DK, Turner MA, Drury JA, Quenby S, Saretzki G, Martin-Ruiz C, et al. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Hum Reprod 2008;23:1511-9. [CrossRef]
28. Mormile R, Vittori G. Endometriosis: a crosstalk between epidermal growth factor (EGF) gene polymorphism and telomerase activity? Eur J Obstet Gynecol Reprod Biol 2011;159:482-3. [CrossRef]
29. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993;169:181-2. [CrossRef]
30. Counter CM, Meyerson M, Eaton E, Ellisen L, Caddle S, Haber D, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998;16:1217-22. [CrossRef]
31. Cheung AN, Zhang DK, Liu Y, Ngan HY, Shen DH, Tsao SW. Telomerase activity in gestational trophoblastic disease. J Clin Pathol 1999;52:588-92. [CrossRef]
32. Nishi H, Yahata N, Ohyashiki K, Isaka K, Shiraishi K, Ohyashiki JH, et al. Comparison of telomerase activity in normal chorionic villi to trophoblastic diseases. Int J Oncol 1998;12:81-5.